News from bioarctic A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 09, 2022, 22:42 ET Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer's disease under the accelerated approval pathway

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have completed the rolling submission to the U.S. Food and...

May 06, 2022, 03:07 ET BioArctic receives new drug substance patent in the US for ABBV-0805 against Parkinson's disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) has granted a new drug substance...

Apr 27, 2022, 02:14 ET Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer's dementia by several years

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that an article about long-term health outcomes of the investigational ...

Apr 20, 2022, 02:11 ET Invitation to presentation of BioArctic's First Quarter Report for January - March 2022 on April 28 at 9.30 a.m. CET

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's First Quarter Report for January - March 2022 on Thursday, April 28, 2022,...

Apr 20, 2022, 02:03 ET AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has announced that the company's partner AbbVie has decided to terminate its collaboration with...

Mar 11, 2022, 02:20 ET Latest lecanemab data to be presented at the AD/PD™ congress

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data relating...

Mar 03, 2022, 19:07 ET Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval

BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of ...

Feb 18, 2022, 02:10 ET BioArctic continues to build its commercial organization

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) continues to build the Nordic commercial organization ahead of a potential launch of the company's...

Jan 27, 2022, 02:13 ET Invitation to presentation of BioArctic's Full Year Report for January - December 2021 on February 3 at 9.30 a.m. CET

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's Full Year Report for January – December 2021 on Thursday, February 3, 2022, ...

Dec 23, 2021, 22:02 ET Lecanemab granted Fast Track designation by the FDA

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab, an investigational anti-amyloid beta (Aβ) protofibril...

Nov 15, 2021, 07:14 ET BioArctic develops new antibody treatment for ALS

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today gave an update on the company's development project ND3014. For the first time, it was announced ...

Nov 15, 2021, 02:20 ET New data on lecanemab presented at the CTAD Alzheimer conference

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai held several oral presentations at the 14th Clinical Trials on Alzheimer's Disease...

Nov 08, 2021, 02:31 ET New data published on ABBV-0805 in Neurobiology of Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has published an article in Neurobiology of Disease describing new preclinical data for the...

Nov 04, 2021, 03:41 ET New data on lecanemab to be presented at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai today announced that they will hold several oral presentations revealing new data on ...

Nov 01, 2021, 03:52 ET BioArctic presents Nomination Committee

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 6, 2021, adopted an instruction regarding the appointment of the...

Oct 11, 2021, 05:13 ET Invitation to presentation of BioArctic's Interim Report for the period January - September 2021 on October 21 at 9.30 a.m. CET

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's Interim Report for the period January – September 2021 on Thursday, October ...

Sep 27, 2021, 23:01 ET Eisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer's disease under the accelerated approval pathway

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that they have initiated a rolling submission to the U.S. Food and...

Sep 10, 2021, 11:00 ET New data presented at MDS Congress of ABBV-0805 in Parkinson's disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present new preclinical data for the investigational anti-α-synuclein antibody ABBV-0805 at the...

Jul 30, 2021, 02:11 ET Eisai presented latest data from the lecanemab clinical program at AAIC 2021

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai held several presentations at the Alzheimer's Association International Conference...

Jul 21, 2021, 03:08 ET Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC)

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer's Association International...

Jul 21, 2021, 02:56 ET Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC)

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer's Association International...

Jun 23, 2021, 19:38 ET FDA grants Breakthrough Therapy designation for lecanemab in Alzheimer's disease

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has granted...

May 11, 2021, 02:16 ET BioArctic receives patent in Japan for new antibodies targeting Alzheimer's disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) has allowed the company's Japanese patent...

Apr 20, 2021, 02:15 ET Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease published in peer-reviewed journal, Alzheimer's Research & Therapy

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b...

Apr 15, 2021, 02:10 ET Invitation to presentation of BioArctic's Interim Report for the period January - March 2021 on April 21 at 9.30 a.m. CET

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's Interim Report for the period January - March 2021 on Wednesday, April 21,...